Optimized Cardioprotection Therapy in Obese Subjects With AMI

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the efficacy and mechanism of Adipokines Cardiac Protection in Obese Patients With acute myocardial infarction (AMI) Who Have Undergone Percutaneous Coronary Intervention (PCI).

Detailed Description
-----------------
Adipokines (or adipocytokines) can be defined as a group of more than 600 bioactive molecules made from adipose tissue that acts as paracrine and endocrine hormones. Adipokines are involved in maintaining varieties of processes such as, appetite and satiety, energy expenditure activity, endothelial function, blood pressure, hemostasis, adipogenesis, insulin sensitivity, energy metabolism in insulin-sensitive tissues, fat distribution and insulin secretion in pancreatic β-cells. Adipokines may contribute to reduce scar formation and improve cardiac function in acute myocardial infarction (AMI). Reperfusion therapy such as percutaneous coronary intervention (PCI) should be administered to all eligible patients with AMI symptom onset within the prior 12 hours. However, our previous work showed that obese patients may benefit more from PCI. Thus, the aim of the present study was to investigate the efficacy and mechanism of adipokines cardiac protection for obese and non-obese patients with acute myocardial infarction (AMI) who have undergone PCI.

Official Title
-----------------
Effects and Mechanism of Adipokines Cardiac Protection in Obese Patients With Acute Myocardial Infarction (AMI) Who Have Undergone Percutaneous Coronary Intervention (PCI).

Conditions
-----------------
Acute Myocardial Infarction, Myocardial Reperfusion Injury, Obesity, Adiposis; Heart

Intervention / Treatment
-----------------
* Procedure: PCI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age between 20 and 70 years old STEMI and NSTMI according to the WHO definition PCI <12 hours from the onset of symptoms Exclusion Criteria: previous myocardial infarction (MI) cardiomyopathy atrial fibrillation or flutter previous heart surgery severe valvular heart disease disease of the hematopoietic system NYHA functional class IV heart failure at baseline severe renal, lung and liver disease cancer

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Obesity<br>Patients with Obesity. BMI>=25 | Procedure: PCI<br>* percutaneous coronary intervention (PCI)<br>|
| Non-Obesity<br>Patients without Obesity. BMI<25 | Procedure: PCI<br>* percutaneous coronary intervention (PCI)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patient death during the follow up period |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Left ventricular ejection fraction |  | 1 year | 
| Myocardial perfusion scores as evaluated by Single-photon emission computed tomography (SPECT) |  | 1 year | 
| Infarct size as evaluated by Single-photon emission computed tomography (SPECT) |  | 1 year | 
| Number of target vessel revascularization |  | 1 year | 
| Angina class according to the canadian cardiovascular society (CCS) classification |  | 1 year | 
| Scores on the Seattle angina questionnaire |  | 1 year | 
| six-min walk distance (6MWD) |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Adiposis, Obesity, Acute Myocardial Infarction, Percutaneous Coronary Intervention, Left Ventricular Function